Hepatocellular carcinoma (HCC) is the second-leading cause of cancer-related deaths worldwide with a poor survival rate. As many as 40% of HCCs are clonal, with alteration of key tumor-suppressor pathways in stem cells as the primary cause of HCC initiation. However, mechanisms that generate metastatic stem cells in preneoplastic liver tissue are not well understood. We hypothesized that chronic inflammation is a major driver of the transformation of genetically defective liver stem cells (LSCs) into highly metastatic liver cancer cells in premalignant liver tissue. We developed models of chronic inflammation in wild-type (WT) and b2-spectrin (b2SP) 1/2 (SPTBN1) mice. H epatocellular carcinoma (HCC) is the fifthmost common cancer and the secondleading cause of cancer-related deaths worldwide.
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Hepatocellular carcinoma (HCC) is the second-leading cause of cancer-related deaths worldwide with a poor survival rate. As many as 40% of HCCs are clonal, with alteration of key tumor-suppressor pathways in stem cells as the primary cause of HCC initiation. However, mechanisms that generate metastatic stem cells in preneoplastic liver tissue are not well understood. We hypothesized that chronic inflammation is a major driver of the transformation of genetically defective liver stem cells (LSCs) into highly metastatic liver cancer cells in premalignant liver tissue. We developed models of chronic inflammation in wild-type (WT) and b2-spectrin (b2SP) 1/2 (SPTBN1) mice. H epatocellular carcinoma (HCC) is the fifthmost common cancer and the secondleading cause of cancer-related deaths worldwide.
(1) HCC accounts for 70%-85% of the total number of primary liver-related malignancies. (2) Owing to its poor prognosis-HCC patients' 5-year survival rate is less than 5%-identifying new therapeutic options for the disease is warranted. (3) The
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clinical course of HCC is related to a broad spectrum of etiological factors, including hepatitis viruses, fatty diets, chronic alcohol consumption, and exposure of hepatotoxins and microorganisms. (4) In addition to these etiological factors, repetitive liver injury can initiate chronic inflammation that can lead to fibrosis, cirrhosis, and, eventually, HCC.
Injured liver tissue has an abundance of the pleiotropic cytokine, transforming growth factor b (TGFb). The TGFb signaling pathway, which has a dynamic effect on HCC development, has a profibrogenic role mediated by activation of hepatic stellate cells (HSCs). As chronic liver disease progresses to fibrosis, cirrhosis, and, finally, HCC, TGFb signaling takes on a tumorsuppressive role. This is evidenced by the downregulation of the TGFb receptor in approximately 25% of large, high-grade HCCs that quickly recur. (5, 6) In vitro administration of recombinant human TGFb2 inhibits the proliferation of HCC cells. (7) For the inhibitory function of TGFb signaling in HCC progression, the dynamic scaffolding protein, b2-spectrin (b2SP), provides key insights into the mechanistic regulation of tumor suppression. b2SP is required to stabilize the small mothers of decapentaplegic (SMAD) 3/SMAD4 complex, which transmits TGFb signaling in the nucleus. (8) Loss of b2SP is frequently detected in human HCC. ) progenitor cells as do wildtype (WT) mice. (9) This finding suggests that b2SP inhibits progenitor cells' transformation from a normal to a malignant phenotype in inflamed liver tissue. Also, in vitro and in vivo functional studies have revealed that b2SP negatively regulates cyclin-dependent kinase 4 (CDK4), cyclin D1, and retinoblastoma protein (3, 10) and corroborating b2SP's critical role in TGFb-induced cell-cycle arrest during the G 1 phase.
Chronic activation of proinflammatory pathways is critical to the progression of hepatitis to liver cancer. Among numerous proinflammatory factors, interleukin-6 (IL6)-mediated signaling has been extensively studied in the context of chronic liver diseases and HCC development. (11) (12) (13) One study found elevated IL6 levels in 40% of liver cancer patients, which suggests that IL6 is associated with HCC progression. (14) Indeed, a high IL6 titer is strongly correlated with adverse prognosis in HCC patients. (15) Also, the TGFb pathway induces IL6 secretion to develop chemotherapeutic resistance in HCC. (16) As a principal mediator of pro-oncogenesis, IL6 is associated with malignant transformation, expansion of cancer stem cells (CSCs), metastasis, and therapeutic resistance in numerous epithelial cancers. (17) (18) (19) Together, these observations strongly suggest that IL6 is associated with the development of CSCs in liver cancer. However, it is not investigated on how IL6 driven inflammation interacts with alteration of the tumorsuppressor pathway to promote CSC initiation.
In injured liver tissue, hepatic stem or progenitor cells must expand to replace damaged hepatocytes, which restore normal liver functions. However, chronic inflammation leads to the secretion of cytokines, chemokines, free radicals, and other DNA-damaging molecules, thereby changing the hepatic microenvironment. (20) Persistent inflammation during this longterm regenerative process leads to an expansion of hepatic stem and progenitor cells that accumulate genetic and epigenetic alterations. Characterizing the bidirectional interaction between stem cells and the hepatic inflammatory milieu would provide great insight into the early phases of HCC initiation. Also, determining whether epithelial-mesenchymal transition (EMT)-positive CSCs are generated during the early phases of HCC initiation is important. Furthermore, elucidating aberrant signaling pathways in EMT 1 CSCs may help to develop specific and individualized therapies for preventing HCC progression.
In this study, we investigated the role of the interaction between deficient TGFb signaling and IL6-mediated chronic inflammation in reprogramming normal liver stem cells (LSCs) to develop into metastatic liver cells (metastatic cancer stem cells; mCSCs). Our results provide a clinically relevant insight into the early development of mCSCs and suggest a potential therapeutic target to eradicate these in pre-neoplastic liver tissue.
Materials and Methods

CHEMICAL REAGENTS AND ANTIBODIES
Collagenase type I, DNase I, and Pronase were purchased from Sigma-Aldrich, Saint Louis, MO. The anti-CD133 antibody was purchased from Miltenyi Biotech, San Diego, CA. The anti-aSMA (alpha-smooth muscle actin), anti-IL6, anti-phosphorylated NFjB (pNFjB; S536), anti-NFjB (nuclear factor kappa B), and anti-TAK1 (TGFb-activated kinase 1) antibodies were purchased from Abcam. The anti-b2SP antibody was a gift from Dr. Lopa Mishra's laboratory. The antipYSTAT3, anti-STAT3 (signal transducer and activator of transcription), anti-TAK1, anti-phosphorylated IjK a/b, and anti-pTAK1 (phosphorylated TAK1) antibodies were purchased from Cell Signaling Technology, Beverly, MA. Anti-inhibitor of jB kinase-b was purchased from R&D systems, Minnneapolis, MN.
MICE
Ten-to 12-week-old female WT and b2SP 1/2 mice were provided by Dr. Lopa Mishra's laboratory. (8) They were maintained in a specific-pathogen-free facility in accord with guidelines approved by the Institutional Animal Care and Use Committee of MD Anderson Cancer Center. The PiggyBac Transposon System (pB513B transposon and Super PB transposase vector) was purchased from System Biosciences, Inc., Palo Alto, CA. Mouse IL6 complementary DNA was obtained from GE Dharmacon, Inc., and subcloned into the pB513B vector. IL6 cytokine-encoding DNA or control plasmid DNA (5 lg in 1.5 mL of 0.45% saline solution per mouse) was injected hydrodynamically through the tail vein twice per month for 3 months. Eight-to 10-week-old female immunodeficient nonobese diabetic/severe combined immunodeficiency (NOD-SCID) gamma chain knockout (NSG) mice were purchased from The Jackson Laboratory, Bar Harbor, ME.
WESTERN BLOTTING
Cell lysis and western blotting with antibodies against pNFjB, NFjB, pTAK1, TAK1, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were performed as described. (21) For all samples, total protein concentrations were determined with a bicinchoninic protein assay kit (Pierce). Western blottings were detected with an enhanced chemiluminescence kit (Cell Signaling Technologies).
ISOLATION AND CULTURE OF PRIMARY TUMOR CELL LINES
Mice were humanely killed after 3 months of treatment or 15-month-old nontreated b2SP 1/2 mouse and singlecell suspension from liver was made as described. (22) A magnet-activated cell-sorting column with an anti-a-CD133 antibody was used to identify CD133 1 LSCs, which were then cultured in poly-D-lysine/laminin-coated plates containing liver-specific supplements in Dulbecco's modified Eagle's medium/F12 media with 10% heatinactivated serum. The liver-specific supplements were rHGF (hepatocyte growth factor; 50 ng/mL), rEGF (epidermal growth factor; 20 ng/mL), insulin-transferrinselenium (13), rFGF (fibroblast growth factor; 20 ng/ mL), dexamethasone (1 3 10 -7 mol/L), and nicotinamide (10 mmol/L). (22) IMMUNOFLUORESCENT
STAINING OF TISSUE SECTIONS
Tissue microarrays (TMAs) of patient liver tissues were purchased from Biomax, Inc., Rockville, MD, in accord with a protocol approved by MD Anderson's Institutional Review Board. Antigen retrieval was performed with heat-induced 13 citrate buffer (SigmaAldrich) for 30 minutes. Tissue staining was performed as described. (23) Stained TMAs were analyzed with the Vectra automated quantitative pathology imaging system (PerkinElmer), which is capable of multispectral imaging. Cell segmentation analysis and protein scoring (based on fluorescence or 3,3 0 -diaminobenzidine staining) were performed using the inForm software program (PerkinElmer).
SCREENING OF CELL SIGNALING PATHWAYS
IL6 b2SP
1/2 LSCs (1 3 10 4 cells/well) were treated with different inhibitors targeting HCCrelated cell signaling pathways for 24 or 48 hours. All inhibitors were used at biologically effective concentrations. To measure the viability of IL6 b2SP
1/2 LSCs after treating with different inhibitors, 100 lL of CyQUANT NF Cell Proliferation Assay reagent was added to each well after aspiration of medium. After incubation for 1 hour at 378C, fluorescence was measured (excitation, 485 nm; emission, 538 nm) on a SpectraMax Geminin EM microplate reader (Molecular Devices).
GENERATION OF NFjB-KNOCKDOWN IN PRIMARY TUMOR CELL LINE
MISSION shNFjB plasmid was purchased from Sigma-Aldrich (NM_009045). Plasmid (5 lg) was nucleofected in IL6 b2SP 1/2 LSCs using AMAXA nucleofector (program Q25). Cells were maintained in puromycin (10 lg/mL) for 3 weeks to grow the NFjB knockdown cell line. NFjB knockdown was confirmed by western blotting with an anti-a-NFjB antibody.
STATISTICAL ANALYSES
Animals were randomly selected for control and treatment groups. All data were calculated as the mean6 the standard error of the mean using GraphPad Prism v5.00. One-way/two-way ANOVA with Tukey's post-hoc test was used to analyze the data. Mann-Whitney's rank sum test was used to calculate the statistical significance of the results. To reduce the bias caused by influential points, we applied linear regression using Huber's M estimator (Huber 1981) for robust estimation when comparing the correlation between IL6 with B2Sp by cancer stage. Ftest was used to assess the overall heterogeneity by stage and t test was used to compare the pairwise difference.
Results
HCC TISSUES HAVE LOW NUCLEAR b2SP ACCUMULATION AND HIGH IL6 LEVELS
The adaptor protein, b2SP, plays an essential role in translocating the SMAD3/SMAD4 complex in the nucleus to drive TGFb-mediated tumor suppression. (24) Thus, the disruption of TGFb signaling by a reduced accumulation of nuclear b2SP is critical to HCC progression. Given the prominent role of nuclear b2SP in the tumor-suppressor activity of TGFb signaling, the nuclear accumulation of b2SP was compared and quantitated by immunohistochemical (IHC) staining in humans with normal, cirrhotic, and HCC liver tissues. In normal liver tissue, b2SP was strongly expressed in both the nucleus (mean IHC score 5 0.188) and the cytoplasm (Fig. 1A) . In contrast, the nuclear accumulation of b2SP was diminished in cirrhotic liver tissue (mean IHC score 5 0.15) and significantly decreased in HCC tissue (mean IHC score 5 0.097; P < 0.0001; Fig. 1C) .
Clinical and preclinical studies have identified a definite association between chronic inflammatory responses and HCC pathogenesis, (25) and accumulating evidence indicates that a high IL6 serum level is associated with the progression of preneoplastic liver to HCC. (25, 26) To investigate this association, we assessed IL6 protein levels in human normal, cirrhotic, and HCC liver tissues. IHC staining revealed that the IL6 expression level in normal liver tissue (mean IHC score 5 0.201) was significantly lower than that in cirrhotic liver tissue (mean IHC score 5 0.251; P 5 0.05; Fig. 1B,D) . The difference between IL6 expression levels of cirrhotic and HCC tissues (mean IHC score 5 0.190) was not significant.
To investigate a possible connection between IL6 protein level and nuclear localization of b2SP in HCC progression, we performed a regression analysis between IL6 protein level to nuclear b2SP in human normal, cirrhotic, and HCC liver tissues. We found that the slopes of the regression for each cancer stage are significantly different (P 5 0.0118). For an increase in IL6, we expect a larger increase of b2SP in the normal group than the cirrhosis group (Db 5 0.1468; P 5 0.046), or a larger increase of b2SP in the cirrhosis group than the HCC group (Db 5 0.1448; P 5 0.0181). Interestingly, our study revealed that higher protein level of IL6 and lower nuclear accumulation of b2SP in patients with cirrhosis shifted the distribution toward the right of the points of normal subjects. SEMs. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, one-way analysis of variance. Abbreviation: ns, not significant.
Paradoxically, the distribution of majority of points in HCC patients were on the left-hand side of the normal subjects. It can be explained by less protein level of IL6 in hepatic tissue of HCC patients and significantly lower accumulation of nuclear b2SP compared to the cirrhotic stage of patients. 1/2 mice treated with pCtr, both WT and b2SP 1/2 mice treated with pIL6 had significantly higher percentages of infiltrating immune cells (P < 0.0001; C) and significantly higher percentages of aSMA protein expression (P < 0.0001; D). (E) Concentration of IL6 in hepatic tissue lysate was measured colorimetrically using an ELISA kit. Compared with those from WT and b2SP 1/2 mice treated with pCtr, hepatic tissue lysates from both WT and b2SP 1/2 mice treated with pIL6 had higher concentrations of IL6 (P < 0.0001). (F) CD133 1 LSCs from WT and b2SP 1/2 mice treated with pIL6 appeared in lysine/laminin-coated plates by day 28; only IL6 b2SP 1/2 LSCs were highly proliferative and formed crypt-shaped structures. (G) IL6 WT LSCs and IL6 b2SP 1/2 LSCs were cultured in suitable supplements containing medium. Cell proliferation was measured using CyQUANT NF Cell Proliferation Assay reagent at day 3 and 6. (H) Representative immunofluorescent confocal microscopy images of Ki67 expression in IL6 WT LSCs (left) and IL6 b2SP 1/2 LSCs (right). Data in panels (C) and (E) and (G) are the means 6 SEMs from two independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, one-way analysis of variance. Abbreviation: ELISA, enzyme-linked immunosorbent assay.
IL6-MEDIATED CHRONIC INFLAMMATION ENABLES TO PROGRAM QUIESCENT CD133
1 LSCs TO BECOME HIGHLY PROLIFERATIVE IN b2SP 1/2 MICE To confirm that reciprocal concurrent IL6 expression and b2SP dysfunction is essential in promoting hepatic tumorigenesis, we established models of IL6-mediated chronic inflammation in both WT and b2SP 1/2 mice by periodic injection of the IL6 gene by hydrodynamic injection once every 2 weeks for 3 months (Fig. 2A) (Fig. 2B) . Significantly greater liver inflammation in WT and b2SP 1/2 mice treated with IL6 than that in the controls was confirmed by histological quantitation (Fig.  2C) . In both WT and b2SP 1/2 mice, fibrosis intensity (as measured by aSMA expression) was closely associated with IL6 expression following IL6 treatment (Fig. 2B,D) . In hepatic tissue lysates, exogenous IL6 expression was linked to inflammation and fibrosis (Fig. 2E) .
After confirmation of chronic inflammation and liver fibrosis following IL6 treatment in both WT and b2SP 1/2 mice, we isolated CD133 1 stem cells from the mice's livers. Under optimal culture conditions, the CD133
1 LSCs from interleukin-6 (pIL6)-treated b2SP 1/2 mice ( IL6 b2SP 1/2 LSCs) were highly proliferative and formed crypt-shaped structures within 2 weeks (Fig. 2F) . Assessing the cells' surface expression of CD133 (Supporting Fig. S1A ), subjecting the cells to sphere-forming assays and staining the spheres for the stem-cell-associated markers, octamer-binding transcription factor 4A (Oct4A) and Nanog (Supporting Fig. S1B,C) , and staining the cells for pluripotency markers, such as stage-specific embryonic antigen 1 and tumor rejection antigen-1-60 (Supporting Fig.  S1D (Fig. 2G) . Also, immunostaining with the proliferation marker, Ki67, showed that IL6 b2SP
1/ 2 LSCs were much more proliferative than IL6 WT LSCs were (Fig. 2H) . These data suggest that the partial disruption of b2SP is critical to acceleration of the development of highly proliferative LSCs subjected to chronic inflammation. LSCs formed more colonies per field than b2SP
CSCs did (Fig. 3A) . In Boyden chamber migration assays, the migratory capacity of IL6 b2SP 1/2 LSCs was 50% greater (P < 0.0001) than that of b2SP
CSCs (Fig. 3B) . Similarly, Matrigel-based invasion assays showed IL6 b2SP 1/2 LSCs to be more invasive than b2SP 1/2 CSCs. Because EMT is associated with increased migration and invasion capacities of tumor cells, we investigated for expression of EMTrelated proteins Twist and Slug.
IL6 b2SP 1/2 LSCs had very high nuclear accumulation of Twist and Slug, whereas these proteins were undetected or present at only basal levels in b2SP 1/2 CSCs (Fig. 3C ). These in vitro data suggest that IL6 b2SP 1/2 LSCs are highly aggressive, EMT-positive cells.
To 1/2 LSCs grew faster than tumors formed by b2SP 1/2 CSCs did (P < 0.0001; Fig. 3D,E) . To determine whether the tumors had the clinicopathological characteristics of HCC, we stained tissue sections with hematoxylin and eosin; IL6 b2SP 1/2 LSCs and b2SP 1/2 CSCs retained all major HCC histological characteristics, such as granular eosinophilic cytoplasm, rounded nuclei, and prominent nucleoli (Fig. 3F) . Also, some mice injected with IL6 b2SP 1/2 LSCs, but no mice injected with b2SP 1/2 CSCs, had spontaneous liver metastasis (2-8 nodules per liver; Fig. 3G,H) . Also, our orthotopic inoculation study showed a similar trend where IL6 b2SP 1/2 LSCs inoculated NSG mice showed significantly (P 5 0.0027) poor survivability compared to b2SP 1/2 CSCs-inoculated NSG mice (Supporting Fig. S2A ). Interestingly, IL6 b2SP
1/2 LSCs-inoculated NSG mice had metastasis in intestinal lymph nodes (Supporting Fig. S2B ). Together, these data exhibited the metastatic nature and EMT phenotypes of IL6 b2SP 1/2 LSCs. 1/2 LSCs and b2SP 1/2 CSCs. Data in panels (B) and (H) are the means 6 SEMs from two independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (Fig.  4A) . However the control cell line, b2SP 1/2 CSCs, did not show any change in viability upon treatment with QNZ for 48 hours (data not shown), which suggested that the constitutive activation of NFjB enables the invasive and metastatic properties of , and (J) are the means 6 SEMs from two independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, one-way analysis of variance. Abbreviations: Hh, hedgehog; HMT, histone methyltransferase; NT, nontreated; PKA, protein kinase A; PTEN, phosphatase and tensin homolog; RFU, relative fluorescence units; TK, tyrosine kinase.
CONSTITUTIVE
LSCs. Western blotting confirmed that QNZ treatment dramatically reduced levels of constitutively phosphorylated NFjB (pNFjB; Fig. 4B ). Immunofluorescent staining confirmed the reduced nuclear accumulation of pNFjB following QNZ treatment (Fig.  4C) . In addition, IL6 b2SP
1/2 LSCs also demonstrated a reduction in nuclear localization and a decrease in the transcriptional activity of pNFjB (Fig. 4D) .
To validate the role of NFjB in driving metastasis, we created IL6 b2SP
1/2 LSCs with stable knockdown of NFjB (shNFjB IL6   b2SP 1/2 LSCs). Knockdown was confirmed by western blotting (Fig. 4E) 1/2 LSCs did (Fig.  4G,H) . The IL6-mediated constitutive activation of STAT3, which has been demonstrated in certain aggressive tumors, (27, 28) is one obvious mechanism underlying the invasive and metastatic nature of IL6 b2SP
1/2 LSCs. However, immunofluorescence staining and western blotting both showed that STAT3 was not constitutively activated or overexpressed in IL6 b2SP
1/2 LSCs (Supporting Fig. S3) .
To understand the clinical relevance of our findings, we stained human normal, cirrhotic, and HCC tissues with antibodies against NFjB and pNFjB. The findings agree with those in the cellular model, in that NFjB phosphorylation levels in HCC tissues and cirrhotic tissues were significantly higher than those in normal tissues (P < 0.0001; Fig. 4I,J) .
To identify the putative serine/threonine kinase(s) responsible for the phosphorylation of the p65 (S536) subunit of NFjB, we treated IL6 b2SP 1/2 LSCs with inhibitors of the kinases, TAK1, inhibitor of IkappaB kinase (IjK), ribosomal S6 kinase 1 (RSK1), protein kinase C (PKC), and casein kinase 2 (CK2), which are known activators of NFjB. (29, 30) Compared with that of untreated control cells, the viability of IL6 b2SP
1/2 LSCs treated with the TAK1 inhibitor was dramatically reduced (P < 0.0001; Fig. 5A ). IKK inhibition had no noticeable effect on the viability of IL6 b2SP 1/2 LSCs or the phosphorylation status of NFjB in IL6 b2SP 1/2 LSCs (Supporting Fig. S4 ). Western blotting analyses revealed that TAK1 inhibition decreased the phosphorylation of NFjB dramatically in IL6 b2SP 1/2 LSCs (Fig. 5B) . Also, TAK inhibition did not alter the total NFjB protein level. This study validated the results of our preliminary screening of the putative kinases with pharmacological inhibitors.
To evaluate the direct association between TAK1 and NFjB, we performed coimmunoprecipitation experiments, which revealed interaction of pNFjB and TAK1 in cell lysates (Fig. 5C ). Coimmunoprecipitation of pNFjB upon TAK1 pulldown from the cell lysate revealed that TAK1 inhibition noticeably decreased the interaction of TAK1 with NFjB (Fig.  5C ). TAK1 and pNFjB were colocalized in the cytoplasm of untreated IL6 b2SP 1/2 LSCs, but this colocalization was dramatically decreased in
LSCs treated with TAK1 inhibitor (Fig. 5D) . Indeed, the TAK1-mediated phosphorylation of NFjB was essential to NFjB-driven reporter activities in IL6 b2SP
1/2 LSCs (Fig. 5E ). These findings strongly showed that TAK1-mediated direct phosphorylation of NFjB facilitates NFjB's transcriptional activity in the nucleus. Also, we are interested to know the direct role of IL6 to activate the TAK1-NFjB pathway in TGFb-disrupted liver tumor cells (Supporting Fig.  S5 ). Our recombinant IL6 (rIL6) treatment on b2SP 1/2 CSCs showed activation of NFjB in 1 hour; however, its activation was attenuated between 4-and 8-hour time points. Interestingly, rIL6 treatment showed inducible protein expression of NFjB in both 4-and 8-hour time points. Western blotting analysis of pTAK1 showed a sustained level of TAK1 activation in b2SP 1/2 CSCs, but its total protein expression did not reflect any significant difference at different points of upon rIL6 treatment.
To substantiate the translational relevance of TAK1 expression with HCC progression, we analyzed the TCGA data set. Mantel-Cox log-rank analysis revealed that the overall survival rate of patients in the TAK1 high group was significantly lower than that of patients in the TAK1 low group (P 5 0.0087; Fig. 5F ). The median survival times for patients in the TAK1 low and TAK1 high groups were 813 and 405 days, respectively. To understand the clinical significance of our findings, we stained human normal, cirrhotic, and HCC tissues with anti-TAK1 and anti-pNFjB antibodies. Our findings agree with those in the cellular model, in that the levels of pNFjB and TAK1 colocalization in advanced HCC tissues and cirrhotic tissues were significantly higher than those in normal tissues (P < 0.0001; Fig. 5G,H) . Together, these findings establish a strong linkage between TAK1-mediated NFjB phosphorylation and liver tumor progression.
In summary, this study provides novel insight into the mechanism by which IL6-driven chronic liver inflammation reprograms normal stem cells to become mCSCs. Stable expression of IL6 in b2SP-deficient murine liver induces chronic inflammation through resident immune cells. This inflammation constitutively activates the protumorigenic TAK1-NFjB signaling pathway to maintain the metastatic phenotypes of liver CSCs (Fig. 6 ).
Discussion
The influence of liver inflammation on oncogenesis has been intensively investigated to increase our comprehension of the underlying molecular mechanisms that may link chronic inflammatory responses with tumor initiation. (31, 32) The prolonged secretion of 6 ) were nucleofected. Transfected cells were treated with or without 500 nM of celastrol for 48 hours. Cells were then lysed, and luciferase activities were measured and normalized. (F) The overall survival rate of HCC patients with low TAK1 gene expression levels (TAK1 low ) was significantly higher than that of HCC patients with high TAK1 gene expression levels (TAK1 high ; P 5 0.0087). (G) Representative images of IHC staining of TAK1 (green) and pNFjB (red) in paraffin-embedded specimens of normal, cirrhotic, and HCC tissues. Nuclei were stained with DAPI (blue). (H) Cytoplasmic colocalization of TAK1 and pNFjB protein levels were scored using inFORM software. Data in panels (A), (E), and (H) are the means 6 SEMs from two independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, one-way analysis of variance. Abbreviations: DAPI, 4 0 ,6-diamidino-2-phenylindole; IP, immunoprecipitation; NT, nontreated; WB, western blotting. cytokines and chemokines during inflammation promotes cancer growth and results in poor host survival. Although the nuclear translocation of b2SP and IL6 levels are inversely related in HCC, metastatic initiation at the preneoplastic tissue had not been reported. To our knowledge, this study is the first to demonstrate that EMT 1 mCSCs can be generated by inflamed livers. This induction depends on the overexpression of IL6 and the partial disruption of TGFb signaling, thus our study extends the current knowledge of IL6's role in promoting liver tumorigenesis. (11, 33, 34) Multiple studies have shown that IL6 or its downstream signaling is capable of expanding CSCs and inducing EMT phenotypes in cancers of the breast, colon, ovary, lung, brain, and head and neck. (35) (36) (37) A recent study showed that STAT3, following its IL6-mediated activation, binds to the promoter element of CD133 to induce HCC progression. (38) Coculturing IL6-secreting tumorassociated macrophages with CD44 1 liver CSCs induces more stemness and tumorigenesis. (11) Determining whether IL6 can interact with other oncogenes or defective tumor suppressors to induce similar types of mCSCs is also of interest. In summary, our findings provide important insights into the reciprocal crosstalk between TGFb signaling and IL6-driven inflammation in preneoplastic liver tissues. However, we did not find any visible tumor incidence in these IL6-treated b2SP 1/2 female mice even after 6 months of posttreatment. The possible explanation could be the protective effect of estrogen to restrict IL6-driven HCC development. (39) The variability in the clinical outcomes of HCC patients is associated with numerous populations of CSCs defined by the markers, CD13, CD24, CD44, CD90, CD133, EpCAM, delta-like 1 homolog, and cell-surface vimentin. (11, 22, 40) The discovery of diverse stem cell markers has increased research into the roles of hepatic stem/progenitor cells in HCC. Liver CSCs are critical to the development of malignant phenotypes, multidrug resistance, and disease relapse in HCC patients. One study revealed that liver cancer patients with high levels of CD133 expression have shorter overall survival and higher relapse rates than those with low levels of CD133 expression. (41) Whether CD133
1 cells contribute to malignancy remains unclear. Several studies have shown that CD133 1 CSCs in HCC are naturally resistant to cytotoxic chemotherapy and other anticancer drugs. (42) Whereas most of these studies have focused on identifying and characterizing CSC surface markers, studies that focus on the tumorigenic or metastatic properties of these cells may be warranted. In addition, the influence of the liver immune microenvironment on modulating these normal stem cells' transition to mCSCs must be investigated. Such investigations would have clinical relevance, including a significant impact on therapeutic strategies.
In liver cancer, sustained inflammation facilitates the progression of fibrosis to cirrhosis and, eventually, HCC. By activating HSCs, the TGFb signaling pathway promotes the progression of chronic inflammation to fibrosis. (43) Paradoxically, by inhibiting cell-cycle regulators and promoting apoptosis, TGFb is instrumental in tumor suppression during the early stages of tumorigenesis. (44, 45) Microarray and proteomic screening of human and mouse HCC tissues have revealed that dysregulated TGFb signaling is associated with the increased expression of pro-oncogenic pathways, such as STAT3, Wnt, and CDK4. (46) Studies have shown that tumors develop in b2SP-haplodeficient mice, and that b2SP expression is significantly reduced in most HCC patients. (8, 9) These findings indicate that TGFb signaling inhibits the development of HCC. Furthermore, screening of human cancer cell lines has revealed that b2SP expression was diminished in Huh-7 cells and reduced by a factor of 9 in SNU-398 cells. (46) One recently published study revealed that b2SP regulates the nuclear localization of bcatenin by increasing the expression of the Wnt inhibitor, kallistatin. (9) Given the importance of b2SP as a regulator of HCC progression, researchers have also investigated its role in the development of liver CSCs. Studies have shown that b2SP inhibition is required for the induction of stemness-associated genes and the genesis of liver CSCs. (47) Decreased b2SP expression in HCC cells facilitates sphere formation, tumor development, and aggressive phenotypes. (9) Furthermore, b2SP
1/2 mice demonstrate a 2-to 4-fold expansion of Oct3/4-positive progenitor cells with activated WNT signaling. (48, 49) The present study shows, for the first time, that the TGFb pathway restrains the development of metastatic clones of HCC CSCs in preneoplastic tissues. Thus, b2SP suppresses the transformation of normal stem cells into expandable liver CSCs.
Our investigation of aberrant molecular pathways in liver CSCs uncovered a novel interaction between TAK1 and NFjB that promotes the EMT-driven metastatic process. A previous study showed that the hepatocyte-specific deletion of TAK1 in mice activates the TGFb signaling pathway to induce spontaneous inflammation, fibrosis, and, eventually, hepatic tumorigenesis. (50) This discovery explains why TAK1-mediated mCSCs occur in livers when TGFb signaling is disrupted as it plays a tumor-suppressor role. Overall, this reciprocal regulation between b2SP and IL6 in the programming of liver CSCs provides insight into the mechanism by which normal stem cells transform into EMT-positive CSCs. Defining the mechanisms by which the loss of b2SP regulates the transition of hepatic stem cells to cells with EMT phenotypes in an inflammation-driven hepatic immune environment may lead to the development of individualized therapies against liver cancer. part, by the National Institutes of Health through MD Anderson's Cancer Center Support Grant CA016672. The University of Texas MD Anderson Cancer Center is supported, in part, by the NCI CCSG Core Grant CA16672.
